Rapidly progressive dyspnea in gastrointestinal stromal tumor (GIST) with imatinib cardiac toxicity

Rapidly progressive dyspnea in gastrointestinal stromal tumor (GIST) with imatinib cardiac toxicity

Gastrointestinal stromal tumors (GISTs) are rare and current estimates range from 4,000 to 6,000 number of GIST cases in the USA annually. Imatinib, a tyrosine kinase inhibitor, has shown a survival benefit in GISTs, and the presence of KIT mutation status is predictive of response. The current case...

Full description

Bibliographic Details
Main Authors: Adnan Asif Parvez Ghias, Shahzeem Bhayani, David J. Gemmel, Sudershan K. Garg
Format: Article
Language:English
Published: Taylor & Francis Group 2018-03-01
Series:Journal of Community Hospital Internal Medicine Perspectives
Subjects:
Gastrointestinal stromal tumors
GISTs
imatinib
cardiac toxicity
heart failure
fluid retention
imatinib toxicity
rare
LV dysfunction
Online Access:http://dx.doi.org/10.1080/20009666.2018.1454787

Internet

http://dx.doi.org/10.1080/20009666.2018.1454787

Similar Items